Suggested remit - To appraise the clinical and cost effectiveness of fostamatinib within its marketing authorisation for treating persistent or chronic immune thrombocytopenia.
Status Proposed
Process STA 2018
ID number 1087

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
06 August 2019 - 04 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
22 October 2018 The company that is developing fostamatinib have shared confidential information with NICE. As a result the Institute will not be progressing with the scoping exercise at this current time. Consequently the consultation on the draft scope will now be closed early. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance